Panminerva medica · 2011
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gulseren A, Peyman B, Pinar A
Аннотация
AIM: The aim of this study was to evaluate the effect of risedronate treatment on OPG, C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), deoxypyridinoline (DPD), and to establish the correlation of OPG levels with other bone turnover markers.
METHODS: Eighty postmenopausal osteoporotic patients were randomized into two groups. In the first group, 37 patients received 35 mg of risedronate once a week, and 600 mg of elementary calcium with 400 IU of vitamin D per day. In the second group, 34 patients received only 600 mg of elementary calcium with 400 IU of vitamin D per day. OPG, OC, CTX and DPD levels were measured at baseline, then at 1, 3 and 6 months of treatment.
RESULTS: OPG levels were significantly reduced at 1 and 6 months of treatment in both the risedronate and control group (p<0.05, p<0.01, respectively), but no statistically significant difference was detected between the two groups (p>0.05). In the group treated with risedronate, a difference in CTX level was observed at 3 months of treatment, while a difference in DPD and OC levels were observed 6 months of treatment. The baseline OPG levels correlated with age, menopause duration and CTX levels. There was no correlation between OPG levels and the levels of the other markers.
CONCLUSION: Our results showed that using risedronate to treat postmenopausal osteoporosis causes no specific changes in OPG levels; thus, measurement of OPG levels as a marker may not be useful in the monitoring of bisphosphonate treatment.
METHODS: Eighty postmenopausal osteoporotic patients were randomized into two groups. In the first group, 37 patients received 35 mg of risedronate once a week, and 600 mg of elementary calcium with 400 IU of vitamin D per day. In the second group, 34 patients received only 600 mg of elementary calcium with 400 IU of vitamin D per day. OPG, OC, CTX and DPD levels were measured at baseline, then at 1, 3 and 6 months of treatment.
RESULTS: OPG levels were significantly reduced at 1 and 6 months of treatment in both the risedronate and control group (p<0.05, p<0.01, respectively), but no statistically significant difference was detected between the two groups (p>0.05). In the group treated with risedronate, a difference in CTX level was observed at 3 months of treatment, while a difference in DPD and OC levels were observed 6 months of treatment. The baseline OPG levels correlated with age, menopause duration and CTX levels. There was no correlation between OPG levels and the levels of the other markers.
CONCLUSION: Our results showed that using risedronate to treat postmenopausal osteoporosis causes no specific changes in OPG levels; thus, measurement of OPG levels as a marker may not be useful in the monitoring of bisphosphonate treatment.